Tests YH32364 in adults with advanced solid tumors that overexpress EGFR
Tests the drug YH32364 in adults with advanced cancer that overexpresses EGFR.
Plain-language title generated from the registry record
Registry title: Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors
Key facts
- Where
- Seoul, South KoreaSee the 4 sites
- Phase
- Phase 1/2
Where in South Korea
- Korea University Anam HospitalSeoul, South KoreaTaking people
- Samsung Medical CenterSeoul, South KoreaTaking people
- Seoul National University HospitalSeoul, South KoreaTaking people
- Severance hospitalSeoul, South KoreaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Yuhan Corporation
- Trial code
- NCT06975410
- Record updated
- 10 June 2026
- Original description
This is a study for people with locally advanced or metastatic cancer for whom previous treatment was not successful. Adults aged 18 and over with advanced cancer with Epidermal Growth Factor Receptor (EGFR) overexpressing can join the study. The purpose of this study is to find out whether a medicine called YH32364 helps people with locally advanced or metastatic cancers with EGFR overexpression.Read full original descriptionShow less
A Phase 1/2, Open-label, Multicenter, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of YH32364 in Patients With Locally Advanced or Metastatic Solid Tumors
This is a study for people with locally advanced or metastatic cancer for whom previous treatment was not successful. Adults aged 18 and over with advanced cancer with Epidermal Growth Factor Receptor (EGFR) overexpressing can join the study. The purpose of this study is to find out whether a medicine called YH32364 helps people with locally advanced or metastatic cancers with EGFR overexpression.
Inclusion: Must sign an informed consent form (ICF) prior to any study specific procedures; ECOG performance status 0 or 1; Estimated life expectancy of at least 3 months; A woman must not be breastfeeding; Have at least one measurable lesion, not previously irradiated and not chosen for biopsy during the study screening period, that can be accurately measured at baseline ≥10 mm in the longest diameter (except lymph nodes which must have a short axis of ≥15 mm) with computerized tomography (CT) or magnetic resonance imaging (MRI), are suitable for accurate repeated measurements; [Dose Escalation Only] Locally advanced or metastatic EGFR overexpressing solid tumor* that is refractory or intolerable on all available standard therapy and that is considered uncurable by local therapy; One of the following pathologically confirmed EGFR overexpressing (IHC3+ or IHC2+) tumors; Head and neck squamous cell carcinoma (HNSCC); Non-small cell lung cancer (NSCLC): squamous cell carcinoma (SqCC); Esophageal squamous cell carcinoma (ESCC); Biliary tract cancer (BTC); Uterine cervical cancer; Vulvar cancer; Urothelial cancer; Squamous cell carcinoma of other origin of tumor (e.g., skin squamous cell tumor); [Dose Expansion Only] Cohort 1: Pathologically confirmed EGFR overexpressing (IHC3+ or IHC2+), locally advanced or metastatic HNSCC other than nasopharyngeal carcinoma (NPC)* that is refractory or intolerable on all available standard therapy and that is considered uncurable by local therapy.
Exclusion: Active chronic hepatitis B or chronic hepatitis C; [Prior/Concomitant Therapy]; Have received systemic steroid therapy; Previous treatment with a 4-1BB/CD137-modulating agent; Have used a live vaccine within 4 weeks; Have received treatment with immunotherapy, biological therapies, targeted small molecules, or hormonal therapies; Have received radiation therapy; Have received cytotoxic chemotherapy; Have history of a second primary cancer with the exception of; curatively treated non-melanomatous skin cancer; curatively treated cervical or breast carcinoma in situ, or; other malignancy with no known active disease present and no treatment administered during the last 2 years; Have history of or current Class II, III or IV heart failure as defined by the New York Heart Association (NYHA); Have history of acute coronary syndromes, including myocardial infarction, coronary artery bypass graft, unstable angina, coronary angioplasty or stenting within past 24 weeks; Have history of (non-infectious) interstitial lung disease (ILD) or pneumonitis that required steroids, or any evidence of current ILD or pneumonitis; Have autoimmune disease that has required systemic treatment; Infection with human immunodeficiency virus (HIV); Known uncontrolled central nervous system (CNS) metastases, spinal cord compression, and/or carcinomatous meningitis.